Abstract:Introduction: Islet xenotransplantation has emerged as a prospective β-cell replacement therapy for insulin-deficient diabetes. Pigs can be genetically modified to protect islet xenografts from immune challenges, including an intense innate response triggered by intraportal delivery, the immediate blood-mediated inflammatory response (IBMIR). The rhesus macaque is one of the most widely used NHP models for islet xenotransplantation. Therefore, we used transgenic porcine islets to treat diabetic rhesus monkeys to verify its effectiveness. Methods: GGTA1P gene knockout and humanized CD55 and CD59 gene insertion were performed on Xeno-1 pigs by CRISPR/Cas9 technology, and the successful insertion of the two gene sequences was confirmed by gene sequencing. Diabetes was induced by i.v. injection of streptozotocin. Rhesus macaques were considered truly diabetic if they had persistent hyperglycemia requiring exogenous insulin administration and were unresponsive to IVGTT and AST. The islets of gene-modified adult pig (over 2 years old) were extracted by enzyme perfusion and continuous density gradient centrifugation. Porcine islets were transplanted into two diabetic monkeys by mesenteric venipuncture. One monkey received 10,000 islet equivalents (IE)/kg and the other 20,000 IE/kg. Graft function was monitored by measuring blood glucose and porcine C-peptide. Results: The first diabetic monkey returned to normal levels of blood glucose 110 days after transplantation. Before the transplantation, the average blood glucose was about 18mmol/L, and the insulin dosage was about 12 IU/day. 110 days after the transplant, the average blood glucose was about 8mmol/L, and the insulin dosage was about 3 IU/day. The amount of insulin is reduced by about 75%. Postoperative D-dimer increased slightly, reached the peak on the 3rd day, and returned to normal on the 5th day. The C-peptide test result was 42.5 pmol/L 3 months after the operation. Blood glucose in the second diabetic monkey returned to normal levels 30 days after transplantation. The average blood glucose was about 17 mmol/L and the insulin dosage was about 12 IU/day before the transplantation. 30 days after transplantation, the average blood glucose was about 7 mmol/L, and the insulin dosage was about 2.5 IU/day. Insulin doses were reduced by approximately 79%. There was no significant fluctuation of D-dimer after operation. Conclusion: GTKO-CD55-CD59-HT adult porcine islets can effectively treat diabetic monkeys. Compared with before transplantation, the blood glucose of the two diabetic monkeys returned to normal after transplantation, the blood glucose fluctuation was small, the average insulin consumption decreased by 77%, and the islet transplantation dosage was positively correlated with the transplantation effect. The blood coagulation indexes after transplantation were basically normal, indicating that there was no postoperative thrombosis. the National Key Research and Development Program (Grant No. 2019YFA0110703).

Xenotransplantation of alginate-chitosan-polyethyleneglycol microencapsulated rat islets in the treatment of mice diabetes mellitus. Preliminary data and future perspective

Xenotransplantation of Alginate-Chitosan-Polyethyleneglycoi Microencapsulated Rat Islets in the Treatment of Mice Diabetes Mellitus

Allotransplantation of sulphate glucomannan-alginate barium (SGA)-microencapsulated rat islets for the treatment of diabetes mellitus.

Comparison of the Efficacy for Diabetic Mice Xenotransplanted with Two Types of Microencapsulated Rat Islets

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Transplantation of Encapsulated Adult Pig Islets in Peritoneal Cavity of Diabetic Mice

The Cytoprotection of Chitosan Based Hydrogels in Xenogeneic Islet Transplantation: an in Vivo Study in Streptozotocin-Induced Diabetic Mouse

Comparison of Efficacy for Diabetic Rats Treated with Two Types of Microencapsulated Adult Pig Pancreatic Islets

Biocompatibility of purified sodium alginate-barium chloride microcapsule and functional assessment of transplanted pancreas islet via the microcapsule for type Ⅰ diabetes

Grafting of Microencapsulated Tilapia Islets to Treat Diabetic Mice

Short-term function and immune-protection of microencapsulated adult porcine islets with alginate incorporating CXCL12 in healthy and diabetic non-human primates without systemic immune suppression: A pilot study

Microencapsulated Pig Islet Xenotransplantation As an Alternative Treatment of Diabetes.

Xenotransplantation of microencapsulated pancreatic islets contained in a vascular prosthesis: preliminary results

A Preliminary Observation on the Immunoisolation Effect of the Microencapsulated SD Rat Islet Grafts by Barium-Alginate Membrane

Subcapsular Implantation of Pancreatic Islets in Syngeneic, Allogeneic, and Xenogeneic Mice.

Correction of Hyperglycemia in Type 1 Diabetic Models by Transplantation of Encapsulated Insulin-Producing Cells Derived from Mouse Embryo Progenitor

316.7: Significant Efficacy of GTKO-CD55-CD59-HT Adult Porcine Islets in Treating Diabetic Monkeys with Xenogeneic Islet Transplantation

Transplant Islets into the Pinna of the Ear: A Mouse Islet Transplant Model

Advantages of the Retroperitoneal Retrocolic Space As the Transplant Site for Encapsulated Xenogeneic Islets.

A Method for Islet Transplantation to the Omentum in Mouse

Reversal of Hyperglycemia in Diabetic Rats by Portal Vein Transplantation of Islet-Like Cells Generated from Bone Marrow Mesenchymal Stem Cells.